{"rows":[{"id":301,"title":"Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat Stress","normalized_title":"contribution of the serotonin 5 ht2a receptor to the therapeutic effect of psilocin on social behavior deficits in mice repeatedly exposed to social defeat stress","authors":"Ibi Daisuke, Takaba Rika, Yoshida Keisuke, Kawase Ririna, Kitagawa Hiroko, Matsushita Momoko, Ito Kana, Uno Shoya, Nishimura Fumiya, Kitagaki Shinji, Hiramatsu Masayuki","abstract":"ABSTRACT Psychedelics such as psilocybin and lysergic acid diethylamide (LSD) exert hallucinogenic effects through stimulation of serotonin 5-HT2A receptors (5-HT2ARs) in the cerebral cortex. In recent years, numerous reports have demonstrated that psychedelics are effective in treating various psychiatric disorders such as major depressive disorder (MDD), treatment-resistant depression (TRD), and anxiety-related disorders. We have previously reported that administration of psilocin, the active metabolite of psilocybin, produces antidepressant-like effects in mice. Furthermore, we found that this effect is mediated by 5-HT2AR activation. Since depression and other psychiatric disorders often lead to impairments in social behavior (e.g., social avoidance), the present study examined the effects of psilocin on social avoidance behavior in mice subjected to chronic social defeat stress (CSDS), a widely used model that closely models human psychosocial stress. Mice exposed to CSDS exhibited social avoidance behavior, whereas psilocin administration before the onset of CSDS had little effect on this behavior. In contrast, psilocin administration after the completion of CSDS ameliorated social avoidance in CSDS-exposed mice. This effect was blocked by pretreatment with a 5-HT2AR antagonist, indicating that psilocin exerts its therapeutic effects through 5-HT2AR activation. Taken together, psilocin exerts therapeutic effects on social avoidance behavior after stress through activation of 5-HT2AR, but not preventive effects when administered before stress, suggesting that psilocin may promote stress resilience rather than resistance.","journal":"Neuropsychopharmacology Reports","publication_date":"2026-08-31","publication_year":2026,"doi":"10.1002/npr2.70152","pubmed_id":"42379141","source_url":"https://doi.org/10.1002/npr2.70152","keywords":"","substance_tags":"psilocybin,psilocin","source_name":"Crossref","date_added":"2026-07-01 06:48:03","last_checked":"2026-07-07 01:20:41","raw_json":"{\"doi\":\"10.1002/npr2.70152\",\"reference_dois\":[\"10.1016/j.cell.2020.03.020\",\"10.1001/jamapsychiatry.2020.3285\",\"10.1007/s00210‐023‐02778‐x\",\"10.3390/pharmaceutics17040411\",\"10.3389/fphar.2024.1391689\",\"10.1542/peds.2008‐1215\",\"10.1186/s12888‐023‐04681‐4\",\"10.1073/pnas.2312662120\",\"10.1016/j.bpsgos.2021.12.009\",\"10.1016/j.biopsych.2016.06.012\",\"10.1016/j.neuroscience.2021.01.029\",\"10.1016/j.neures.2022.12.015\",\"10.1038/nprot.2011.361\",\"10.1016/s0031‐9384(01)00490‐5\",\"10.1111/ejn.15812\",\"10.1016/j.neuropharm.2018.01.016\",\"10.1021/acschemneuro.9b00493\",\"10.1016/j.neuron.2007.01.008\",\"10.1016/j.bbi.2012.12.017\"],\"reference_count\":19,\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W7166665532\",\"openalex_url\":\"https://openalex.org/W7166665532\",\"openalex_relevance_score\":12,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\",\"title:psilocin\",\"abstract:psilocin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1970090557\",\"https://openalex.org/W1977593923\",\"https://openalex.org/W2009134620\",\"https://openalex.org/W2430804118\",\"https://openalex.org/W2783004241\",\"https://openalex.org/W3010499243\",\"https://openalex.org/W3015140823\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3127490177\",\"https://openalex.org/W4206083694\",\"https://openalex.org/W4293199581\",\"https://openalex.org/W4312054389\",\"https://openalex.org/W4389040484\",\"https://openalex.org/W4396224564\",\"https://openalex.org/W4408808337\"],\"authorships\":[{\"id\":\"https://openalex.org/A5139664214\",\"display_name\":\"Daisuke Ibi\",\"orcid\":null},{\"id\":\"https://openalex.org/A5076092672\",\"display_name\":\"Rika Takaba\",\"orcid\":null},{\"id\":\"https://openalex.org/A5079107661\",\"display_name\":\"Keisuke Yoshida\",\"orcid\":\"https://orcid.org/0000-0002-8384-9418\"},{\"id\":\"https://openalex.org/A5108412221\",\"display_name\":\"R. Kawase\",\"orcid\":null},{\"id\":\"https://openalex.org/A5048244424\",\"display_name\":\"Hiroko Kitagawa\",\"orcid\":null},{\"id\":\"https://openalex.org/A5139661865\",\"display_name\":\"Momoko Matsushita\",\"orcid\":null},{\"id\":\"https://openalex.org/A5139634014\",\"display_name\":\"Kana Ito\",\"orcid\":null},{\"id\":\"https://openalex.org/A5030080970\",\"display_name\":\"Shoya Uno\",\"orcid\":null},{\"id\":\"https://openalex.org/A5139632842\",\"display_name\":\"Fumiya Nishimura\",\"orcid\":null},{\"id\":\"https://openalex.org/A5014830673\",\"display_name\":\"Shinji Kitagaki\",\"orcid\":\"https://orcid.org/0000-0001-7496-7773\"},{\"id\":\"https://openalex.org/A5139711108\",\"display_name\":\"Masayuki Hiramatsu\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210189692\",\"source_display_name\":\"Neuropsychopharmacology Reports\",\"landing_page_url\":\"https://doi.org/10.1002/npr2.70152\",\"is_oa\":true}}}","topic_tags":"Depression,Anxiety,Receptor Pharmacology,Resilience,Animal Study,Treatment-Resistant Depression","study_type":"Animal Study","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7166665532"},{"id":5677,"title":"CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder.","normalized_title":"csf galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder","authors":"Paslawski W, Doyon D, Ekman CJ, Yngwe H, Mamula D, Zareba-Paslawska J, Beckman M, Xu ZD, Hökfelt T, Tiger M, Lundberg J, Svenningsson P.","abstract":"Psilocybin is a rapid-acting antidepressant, but its mechanism of action in major depressive disorder remains unclear. In this secondary analysis of randomized, placebo-controlled trial with multimodal CSF and blood biomarker measurements, psilocybin selectively reduced CSF galanin and noradrenaline, implicating that normalization of these co-transmitters is a key pharmacodynamic signature.","journal":"Neuropsychopharmacology","publication_date":"2026-07-06","publication_year":2026,"doi":"10.1038/s41386-026-02490-3","pubmed_id":"42414566","source_url":"https://doi.org/10.1038/s41386-026-02490-3","keywords":"","substance_tags":"psilocybin","source_name":"Europe PMC","date_added":"2026-07-08 01:20:22","last_checked":"2026-07-09 01:20:16","raw_json":"{\"europe_pmc_id\":\"42414566\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W7167637338\",\"openalex_url\":\"https://openalex.org/W7167637338\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1981734883\",\"https://openalex.org/W2014887176\",\"https://openalex.org/W2040649786\",\"https://openalex.org/W2092170736\",\"https://openalex.org/W2175268588\",\"https://openalex.org/W2201607793\",\"https://openalex.org/W2461590308\",\"https://openalex.org/W2560044495\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W4205208574\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4386504040\",\"https://openalex.org/W4405890096\",\"https://openalex.org/W7161294763\"],\"authorships\":[{\"id\":\"https://openalex.org/A5026281113\",\"display_name\":\"Wojciech Pasławski\",\"orcid\":\"https://orcid.org/0000-0003-2141-4547\"},{\"id\":\"https://openalex.org/A5026248580\",\"display_name\":\"D Doyon\",\"orcid\":null},{\"id\":\"https://openalex.org/A5045856839\",\"display_name\":\"Carl Johan Ekman\",\"orcid\":\"https://orcid.org/0000-0002-3770-9385\"},{\"id\":\"https://openalex.org/A5095379592\",\"display_name\":\"Hampus Yngwe\",\"orcid\":null},{\"id\":\"https://openalex.org/A5086436715\",\"display_name\":\"Dejan Mamula\",\"orcid\":\"https://orcid.org/0000-0002-8215-7794\"},{\"id\":\"https://openalex.org/A5027605872\",\"display_name\":\"Justyna Zarȩba-Pasławska\",\"orcid\":\"https://orcid.org/0000-0001-6193-5908\"},{\"id\":\"https://openalex.org/A5065682565\",\"display_name\":\"Maria Beckman\",\"orcid\":\"https://orcid.org/0000-0002-9370-1863\"},{\"id\":\"https://openalex.org/A5024639719\",\"display_name\":\"Qing Xu\",\"orcid\":\"https://orcid.org/0000-0002-0387-7559\"},{\"id\":\"https://openalex.org/A5140192339\",\"display_name\":\"Tomas Hökfelt\",\"orcid\":null},{\"id\":\"https://openalex.org/A5063179816\",\"display_name\":\"Mikael Tiger\",\"orcid\":\"https://orcid.org/0000-0001-8495-8125\"},{\"id\":\"https://openalex.org/A5082468471\",\"display_name\":\"Johan Lundberg\",\"orcid\":\"https://orcid.org/0000-0002-4298-3936\"},{\"id\":\"https://openalex.org/A5036364090\",\"display_name\":\"Per Svenningsson\",\"orcid\":\"https://orcid.org/0000-0001-6727-3802\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S175030738\",\"source_display_name\":\"Neuropsychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1038/s41386-026-02490-3\",\"is_oa\":true}}}","topic_tags":"Depression,Pharmacology,Mechanism of Action,Biomarkers","study_type":"Clinical Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7167637338"},{"id":5674,"title":"Psilocybe Poisoning: Pathophysiology, Classification and Treatment. A Clinical Case Review","normalized_title":"psilocybe poisoning pathophysiology classification and treatment a clinical case review","authors":"Omar Azuara-Antonio, Erika Rubí De La Cruz-Elizaldeb, José Eduardo Carmona-Rodriguez, Lesly Idaliht Hernandez-Martinez","abstract":"The Psilocybe cubensis mushroom is recognized as the primary source of psilocybin in the Americas, occurring naturally across various regions. This fungus has a long history of use in Mesoamerican rituals due to its capacity to induce altered states of consciousness. The defining characteristic of Psilocybe mushrooms is their psilocybin content. Following ingestion, psilocybin is metabolized into psilocin, which acts as a potent serotonergic agonist by interacting with serotonin receptors. The resulting physiological and psychoactive effects are linked to the activity at 5-HT receptors within the central nervous system, along with the release of glutamate. Throughout history, diverse Mesoamerican cultures incorporated hallucinogenic mushroom consumption into their ritual ceremonies. The Aztecs, for example, revered them as Teonanácatl, or \" flesh of the gods,\" valuing their ability to shift the perception of reality. Interest in psilocybin has seen a resurgence in the scientific community, spanning from the ethnobotanical studies of R. Gordon Wasson in the 1950s to contemporary research into its therapeutic applications for depression. Studies have indicated that psilocybin can sustainably alleviate depressive symptoms, often with fewer side effects compared to conventional pharmacological treatments. The combination of the ancient ceremonial and religious use of Psilocybe mushrooms with their demonstrable therapeutic potential is prompting a reevaluation of their legal status as a Schedule I drug. Ongoing research is actively exploring the impact of psilocybin on various psychiatric disorders, yielding promising results, particularly in the treatment of major depressive disorder. As the evidence supporting its therapeutic benefits continues to accumulate, it suggests a future where these psychedelic compounds could play a vital role in global mental health.","journal":"Mexican Journal of Medical Research ICSA","publication_date":"2026-07-04","publication_year":2026,"doi":"10.29057/mjmr.v14i28.16493","pubmed_id":null,"source_url":"https://doi.org/10.29057/mjmr.v14i28.16493","keywords":"Psilocybin, Serotonergic, Hallucinogen, Trance, Psychology, Pharmacology, Traditional medicine, Medicine, Neuroscience, Serotonin Agonist, Ayahuasca, Agonist, Amphetamine, Psychiatry, 5-HT2 receptor, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Chemical synthesis and alkaloids","substance_tags":"psilocybin,psilocin","source_name":"OpenAlex","date_added":"2026-07-07 01:20:41","last_checked":"2026-07-09 01:20:16","raw_json":"{\"openalex_id\":\"https://openalex.org/W7167422156\",\"openalex_url\":\"https://openalex.org/W7167422156\",\"openalex_relevance_score\":10,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\",\"abstract:psilocin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5051415806\",\"display_name\":\"Omar Azuara-Antonio\",\"orcid\":\"https://orcid.org/0000-0002-8648-4573\"},{\"id\":\"https://openalex.org/A5140086242\",\"display_name\":\"Erika Rubí De La Cruz-Elizaldeb\",\"orcid\":null},{\"id\":\"https://openalex.org/A5140068470\",\"display_name\":\"José Eduardo Carmona-Rodriguez\",\"orcid\":\"https://orcid.org/0009-0002-9952-3356\"},{\"id\":\"https://openalex.org/A5140080438\",\"display_name\":\"Lesly Idaliht Hernandez-Martinez\",\"orcid\":\"https://orcid.org/0009-0002-2027-9574\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210193124\",\"source_display_name\":\"Mexican Journal of Medical Research ICSA\",\"landing_page_url\":\"https://doi.org/10.29057/mjmr.v14i28.16493\",\"is_oa\":true}}","topic_tags":"Depression,Pharmacology,Receptor Pharmacology,Consciousness,Review Article,Adverse Events,Toxicity","study_type":"Review Article","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7167422156"},{"id":3978,"title":"Trajectories of psychedelic-assisted change: An observational study of a psilocybin retreat program followed by psychotherapeutic interventions","normalized_title":"trajectories of psychedelic assisted change an observational study of a psilocybin retreat program followed by psychotherapeutic interventions","authors":"Whitfield Henry J., Schepers Jan, Mason Natasha L., Luca Maria, Kuypers Kim P. C.","abstract":"Abstract Despite growing interest in psychedelic-assisted psychotherapy, research investigating the psychotherapeutic components is lacking. This leaves unanswered questions regarding the psychotherapy's necessity and form. This observational study addresses this gap by measuring the outcomes of a psilocybin truffle retreat, followed by the outcomes of two psychotherapy interventions that targeted psychological content from the retreat ( n = 50). Participants attended an Acceptance and Commitment Therapy (ACT)-informed psilocybin retreat program followed by psychotherapy. Mid-data collection the psychotherapy intervention was revised: ACT-SPT ( n = 23; self-perspective taking and cognitive defusion) was altered to ACT-PMNR ( n = 27; Psychedelic Memory Network Reexperiencing). Both approaches aimed to support long-term psychological change. Participants completed measures of Depression, Anxiety, Stress (DASS-21), Valued Living (VLQ), and measures of Psychological Flexibility, Mindfulness, Cognitive Fusion, Well-being and Life Functioning at four time points: baseline, post-psilocybin, post-psychotherapy and follow-up. For the combined effect of retreat and subsequent interventions, a Linear Mixed Model (LMM) analysis found significant changes in all measures. Comparing psychotherapy trajectories, there was a significant Time × Intervention interaction for DASS-21 (Anxiety), CORE-5 (Well-being, Life Functioning). During the post-psilocybin period, ACT-SPT trajectories drifted towards baseline levels, whilst ACT-PMNR continued to improve. Long-term LMM follow-up of ACT-PMNR trajectories showed significant change across all measures. Penalized spline growth curves showed that post-therapy change exceeded baseline-to-post-retreat change. At follow-up these trajectories often sustained or further improved. Conclusions Targeted post-psilocybin interventions may further build on the initial psilocybin retreat result. These interventions may drive measurable changes in the specific domains they engage. Randomized studies are warranted to confirm these findings.","journal":"Journal of Psychedelic Studies","publication_date":"2026-07-02","publication_year":2026,"doi":"10.1556/2054.2026.00530","pubmed_id":null,"source_url":"https://doi.org/10.1556/2054.2026.00530","keywords":"","substance_tags":"psilocybin","source_name":"Crossref","date_added":"2026-07-04 01:20:27","last_checked":"2026-07-09 01:20:16","raw_json":"{\"doi\":\"10.1556/2054.2026.00530\",\"reference_dois\":[\"10.1007/s00213-024-06620-x\",\"10.1007/bf00401404\",\"10.1177/1073191105283504\",\"10.1177/1073191107313003\",\"10.1002/9780470687994.ch8\",\"10.1038/s41598-020-59282-y\",\"10.1001/jamapsychiatry.2022.2096\",\"10.1016/j.beth.2011.03.007\",\"10.1093/oxfordhb/9780190088224.013.29\",\"10.1007/s00213-017-4771-x\",\"10.1177/0269881118754710\",\"10.1097/psy.0000000000000233\",\"10.1348/014466503321903544\",\"10.1016/j.jpsychires.2021.08.017\",\"10.3389/fpsyg.2018.01028\",\"10.1371/journal.pone.0246434\",\"10.1192/bjp.180.1.51\",\"10.3758/bf03193146\",\"10.1016/j.jcbs.2016.05.003\",\"10.1080/09540261.2018.1486289\",\"10.1300/j146v12n01_08\",\"10.1016/j.beth.2013.08.001\",\"10.1177/0269881116675513\",\"10.1016/s2215-0366(23)00363-2\",\"10.1037/pas0000263\",\"10.3389/fpsyt.2022.946615\",\"10.1007/bf03395492\",\"10.1016/s0006-3223(01)01157-x\",\"10.1016/j.psyneuen.2008.03.008\",\"10.1192/bjp.bp.112.125286\",\"10.1038/s41598-020-61169-x\",\"10.1177/0269881114548296\",\"10.1080/03004279.2023.2257216\",\"10.1002/cpp.479\",\"10.1016/0005-7967(94)00075-u\",\"10.1080/02791072.2020.1769878\",\"10.1037/a0026070\",\"10.3389/fphar.2018.00256\",\"10.3389/fpsyt.2022.1025726\",\"10.1016/j.brat.2003.10.008\",\"10.1111/acps.13778\",\"10.2147/ndt.s432537\",\"10.1111/psyp.14756\",\"10.1038/s41586-023-06204-3\",\"10.1177/0269881118780612\",\"10.1016/j.cell.2020.03.020\",\"10.1080/00207594.2012.755535\",\"10.1001/jamanetworkopen.2022.49422\",\"10.1176/appi.ajp.2018.18070834\",\"10.1176/appi.ajp.20220216\",\"10.1001/jamanetworkopen.2023.12434\",\"10.1177/0022167816670996\",\"10.1177/0269881116675512\",\"10.1176/appi.psychotherapy.2002.56.1.59\",\"10.1177/20503245241235100\",\"10.1016/j.jcbs.2024.100854\",\"10.1016/j.jcbs.2014.06.001\",\"10.1037/met0000193\",\"10.1177/0022167817715966\",\"10.1002/da.23065\",\"10.1038/s41598-023-36184-3\",\"10.3389/fpsyt.2021.727572\",\"10.1007/bf03395706\",\"10.1016/j.beth.2014.07.002\"],\"reference_count\":140,\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W7167262029\",\"openalex_url\":\"https://openalex.org/W7167262029\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W848231126\",\"https://openalex.org/W1499135245\",\"https://openalex.org/W1723026158\",\"https://openalex.org/W1749626057\",\"https://openalex.org/W1818523973\",\"https://openalex.org/W1966524739\",\"https://openalex.org/W1990781714\",\"https://openalex.org/W2004719903\",\"https://openalex.org/W2007316404\",\"https://openalex.org/W2009710620\",\"https://openalex.org/W2011362078\",\"https://openalex.org/W2034824117\",\"https://openalex.org/W2038015193\",\"https://openalex.org/W2062682953\",\"https://openalex.org/W2062989629\",\"https://openalex.org/W2064471675\",\"https://openalex.org/W2076298754\",\"https://openalex.org/W2087484885\",\"https://openalex.org/W2114350740\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2137111843\",\"https://openalex.org/W2141674457\",\"https://openalex.org/W2148011665\",\"https://openalex.org/W2165847290\",\"https://openalex.org/W2255259502\",\"https://openalex.org/W2263745924\",\"https://openalex.org/W2395013989\",\"https://openalex.org/W2525190545\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2626493232\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2788854095\",\"https://openalex.org/W2796179442\",\"https://openalex.org/W2807347332\",\"https://openalex.org/W2809850625\",\"https://openalex.org/W2886736785\",\"https://openalex.org/W2900604419\",\"https://openalex.org/W2935676591\",\"https://openalex.org/W3005441929\",\"https://openalex.org/W3009608926\",\"https://openalex.org/W3015140823\",\"https://openalex.org/W3035643259\",\"https://openalex.org/W3038388367\",\"https://openalex.org/W3128065860\",\"https://openalex.org/W3196180891\",\"https://openalex.org/W4200524305\",\"https://openalex.org/W4213367182\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4296710292\",\"https://openalex.org/W4304842777\",\"https://openalex.org/W4311508922\",\"https://openalex.org/W4313544481\",\"https://openalex.org/W4375954983\",\"https://openalex.org/W4380089845\",\"https://openalex.org/W4380684709\",\"https://openalex.org/W4386603958\",\"https://openalex.org/W4389606379\",\"https://openalex.org/W4391053730\",\"https://openalex.org/W4392249465\",\"https://openalex.org/W4398774731\",\"https://openalex.org/W4404565171\",\"https://openalex.org/W4405021720\",\"https://openalex.org/W4406768953\"],\"authorships\":[{\"id\":\"https://openalex.org/A5109831612\",\"display_name\":\"Henry J. Whitfield\",\"orcid\":null},{\"id\":\"https://openalex.org/A5016439728\",\"display_name\":\"Jan Schepers\",\"orcid\":\"https://orcid.org/0000-0002-6511-7651\"},{\"id\":\"https://openalex.org/A5139963227\",\"display_name\":\"Natasha L. Mason\",\"orcid\":null},{\"id\":\"https://openalex.org/A5017592857\",\"display_name\":\"Maria Luca\",\"orcid\":\"https://orcid.org/0000-0003-0416-4718\"},{\"id\":\"https://openalex.org/A5024651565\",\"display_name\":\"Kim P. C. Kuypers\",\"orcid\":\"https://orcid.org/0000-0001-7634-3809\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210226251\",\"source_display_name\":\"Journal of Psychedelic Studies\",\"landing_page_url\":\"https://doi.org/10.1556/2054.2026.00530\",\"is_oa\":true}}}","topic_tags":"Depression,Anxiety,Wellbeing,Psychological Flexibility,Observational Study,Drug Interactions","study_type":"Clinical Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7167262029"},{"id":3975,"title":"Sexual identity as a moderator of associations between lifetime MDMA/ecstasy or psilocybin use and mental health outcomes: An exploratory analysis of a nationally representative sample using NSDUH 2015-2019","normalized_title":"sexual identity as a moderator of associations between lifetime mdma ecstasy or psilocybin use and mental health outcomes an exploratory analysis of a nationally representative sample using nsduh 2015 2019","authors":"Seale M.","abstract":"Abstract Purpose Lifetime MDMA/ecstasy and psilocybin use have been associated with lower odds of psychological distress, suicidality, and depressive episodes, but these associations may vary by marginalized identity. Building on minorities' diminished psychedelic returns (MDPR) framework and extending Jones and Nock's race/ethnicity moderation work, this study tests whether sexual identity moderates them. Methods This cross-sectional secondary analysis used pooled NSDUH 2015-2019 data (N = 210,392 adults). Survey-weighted logistic regressions tested whether sexual identity moderated associations between lifetime MDMA/ecstasy or psilocybin use and six mental health outcomes. In a two-step exploratory design, full-sample interactions were screened first, with subgroup models tested only for substance-outcome combinations showing significant moderation (p ≤.05). Results Lifetime MDMA/ecstasy and psilocybin use were more common among bisexual and lesbian/gay than heterosexual respondents. Bisexual identity moderated psilocybin associations with past-year suicidal ideation (p =.03579) and severe past-year major depressive episode (MDE; p =.04950); no other interactions were significant. In subgroup models, psilocybin was associated with reduced severe past-year MDE among heterosexual (aOR = 0.85 [0.74, 0.98], p =.03170) but not bisexual respondents. No subgroups showed a psilocybin-suicidal-ideation association. Conclusion This data provides little support for MDPR as applied to sexual identity: most sexual-identity-by-substance interactions were null and none survived false-discovery-rate correction. The two psilocybin-bisexual signals are hypothesis-generating at most, but the bisexual specificity suggests differences in social and integration support may shape whether psychedelic exposure benefits mental health.","journal":"Research Square","publication_date":"2026-07-01","publication_year":2026,"doi":"10.21203/rs.3.rs-10208910/v1","pubmed_id":null,"source_url":"https://doi.org/10.21203/rs.3.rs-10208910/v1","keywords":"","substance_tags":"psilocybin","source_name":"Europe PMC","date_added":"2026-07-03 01:20:31","last_checked":"2026-07-09 01:20:12","raw_json":"{\"europe_pmc_id\":\"PPR1264241\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Research Square\",\"importer\":\"Europe PMC\"}","topic_tags":"Depression,Observational Study,Drug Interactions","study_type":"Observational Study","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"preprint","openalex_id":null},{"id":3812,"title":"Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms","normalized_title":"past year psilocybin and alcohol co use associations with mental health symptoms","authors":"Hummel Haley M., Obrochta Alexia N., Kerr David C. R., Cservenka Anita","abstract":"Interest has grown in the effects of psilocybin on mental health, but little is known about its naturalistic use alongside alcohol and its relationship to depression and/or anxiety symptoms. Data from the nationally-representative 2024 National Survey Investigating Hallucinogenic Trends of participants who did ( n = 1234) or did not ( n = 1607) report past-year psilocybin and alcohol co-use were compared on depressive and anxiety symptoms and poor mental health days. Weighted regressions adjusted for age, sex, survey collection period, race, ethnicity, and past-year cannabis and other psychedelic use. Individuals with psilocybin and alcohol co-use had fewer depressive symptoms ( B (SE) = −.57(.28), β = −.04, p =.043) than those who used alcohol without psilocybin, suggesting potential benefits of psilocybin in individuals with co-use. After removing cannabis and other psychedelic use covariates, psilocybin use was also related to lower anxiety symptoms. However, given the observational and self-report study design, causal inferences cannot be made. Thus, longitudinal and experimental studies are needed.","journal":"Journal of Drug Issues","publication_date":"2026-06-30","publication_year":2026,"doi":"10.1177/00220426261466154","pubmed_id":null,"source_url":"https://doi.org/10.1177/00220426261466154","keywords":"","substance_tags":"psilocybin","source_name":"Crossref","date_added":"2026-07-02 06:54:51","last_checked":"2026-07-08 01:20:28","raw_json":"{\"doi\":\"10.1177/00220426261466154\",\"reference_dois\":[\"10.52965/001c.127794\",\"10.2196/15830\",\"10.1001/jamahealthforum.2025.4011\",\"10.1007/s11469-023-01163-2\",\"10.1111/acer.14518\",\"10.1111/adb.13229\",\"10.15288/jsa.1993.54.326\",\"10.1037/1040-3590.6.2.117\",\"10.1080/09687637.2023.2236291\",\"10.20944/preprints202506.1536.v1\",\"10.1097/01.alc.0000081617.37539.d6\",\"10.3389/fpsyt.2019.00955\",\"10.1016/j.psychres.2020.112749\",\"10.1016/j.jad.2023.01.108\",\"10.15288/jsad.23-00312\",\"10.1016/j.dscb.2025.100286\",\"10.1080/02791072.2022.2044096\",\"10.15288/jsa.2001.62.190\",\"10.1001/jamapsychiatry.2025.3038\",\"10.1556/2054.2023.00243\",\"10.1007/s00213-011-2236-1\",\"10.1016/j.biopsych.2014.04.010\",\"10.1046/j.1525-1497.2001.016009606.x\",\"10.1016/j.drugpo.2024.104507\",\"10.1177/02698811241292956\",\"10.3390/molecules26102948\",\"10.1016/0306-4603(96)00042-1\",\"10.1136/bmj-2023-078084\",\"10.3389/fpsyt.2024.1429373\",\"10.3389/fpsyt.2023.1199642\",\"10.1038/s41429-020-0311-8\",\"10.1073/pnas.1524187113\",\"10.1111/add.13757\",\"10.1176/appi.ajp.2019.19010035\",\"10.7326/annals-24-03145\",\"10.3389/fpsyg.2021.729425\",\"10.1038/s44220-026-00630-8\",\"10.1001/archinte.166.10.1092\",\"10.1080/02791072.2022.2039815\",\"10.1038/nrn2884\",\"10.1146/annurev-psych-040422-045007\"],\"reference_count\":50,\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W7166830239\",\"openalex_url\":\"https://openalex.org/W7166830239\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W2022417404\",\"https://openalex.org/W2043705607\",\"https://openalex.org/W2068751924\",\"https://openalex.org/W2093203605\",\"https://openalex.org/W2112692374\",\"https://openalex.org/W2118588896\",\"https://openalex.org/W2129497492\",\"https://openalex.org/W2132322340\",\"https://openalex.org/W2139781346\",\"https://openalex.org/W2167163337\",\"https://openalex.org/W2336591896\",\"https://openalex.org/W2589841225\",\"https://openalex.org/W2981471416\",\"https://openalex.org/W2996870046\",\"https://openalex.org/W3001327571\",\"https://openalex.org/W3006905788\",\"https://openalex.org/W3025824861\",\"https://openalex.org/W3102139776\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3204171992\",\"https://openalex.org/W4213229867\",\"https://openalex.org/W4214488648\",\"https://openalex.org/W4293870301\",\"https://openalex.org/W4294308393\",\"https://openalex.org/W4319067008\",\"https://openalex.org/W4323049021\",\"https://openalex.org/W4385304034\",\"https://openalex.org/W4386861633\",\"https://openalex.org/W4387035369\",\"https://openalex.org/W4396588878\",\"https://openalex.org/W4400043767\",\"https://openalex.org/W4401821604\",\"https://openalex.org/W4403848501\",\"https://openalex.org/W4403895310\",\"https://openalex.org/W4406091421\",\"https://openalex.org/W4409632414\",\"https://openalex.org/W4411500561\",\"https://openalex.org/W4414440106\",\"https://openalex.org/W4415929140\",\"https://openalex.org/W4416008630\",\"https://openalex.org/W7151101131\"],\"authorships\":[{\"id\":\"https://openalex.org/A5107648241\",\"display_name\":\"Haley M Hummel\",\"orcid\":null},{\"id\":\"https://openalex.org/A5116118092\",\"display_name\":\"Alexia N Obrochta\",\"orcid\":null},{\"id\":\"https://openalex.org/A5139789016\",\"display_name\":\"David C. R. Kerr\",\"orcid\":null},{\"id\":\"https://openalex.org/A5088076764\",\"display_name\":\"Anita Cservenka\",\"orcid\":\"https://orcid.org/0000-0003-0813-5201\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S57770130\",\"source_display_name\":\"Journal of Drug Issues\",\"landing_page_url\":\"https://doi.org/10.1177/00220426261466154\",\"is_oa\":false}}}","topic_tags":"Depression,Anxiety,Observational Study","study_type":"Observational Study","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7166830239"},{"id":3811,"title":"Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.","normalized_title":"investigating the impact of serotonergic psychedelic drugs mdma and ketamine on social cognition in psychiatric disorders a scoping review","authors":"Smith SA, Mohammad H, Lee LHN, Dennett L, Smith S, Burback L, Winkler O, Greenshaw A, Jetly R, Kennedy SH, Bhat V, Swainson J, Vermetten E, Cao B, Li XM, Zhang Y.","abstract":"RationaleInterest in psychedelic drugs has increased rapidly because of their potential therapeutic role in psychiatric disorders. Impairments in the sociocognitive skills needed to build and maintain social relationships are prominent features of many psychiatric and neurodevelopmental disorders. Emerging evidence suggests that compounds such as 3,4-methylenedioxymethamphetamine (MDMA), lysergic acid diethylamide (LSD), and psilocybin may influence these impairments.ObjectivesThis review aimed to determine whether psychedelic drugs may modulate social cognition in individuals with psychiatric or neurodevelopmental disorders associated with cognitive impairment.MethodsA search of the MEDLINE, PsycINFO, EMBASE, and Scopus databases was conducted. Twenty studies were identified that evaluated the effects of ketamine, MDMA, psilocybin, LSD, and ayahuasca in depressive disorders, anxiety disorders, autism spectrum disorder (ASD), and post-traumatic stress disorder (PTSD).ResultsFindings included neural activation patterns suggesting that ketamine and psilocybin may modulate processes relevant to social perception, particularly facial emotion processing, in depressive disorders. Positive findings were also reported for MDMA in participants with PTSD, including improvements in self-reported psychosocial functioning, self-awareness, and self-compassion.ConclusionsCurrent evidence suggests that psychedelic drugs may modulate processes relevant to social cognition in psychiatric disorders, although direct evidence of improved social-cognitive functioning remains limited.Clinical trial numberNot applicable.","journal":null,"publication_date":"2026-06-30","publication_year":2026,"doi":"10.1007/s00213-026-07110-y","pubmed_id":"42380668","source_url":"https://doi.org/10.1007/s00213-026-07110-y","keywords":"","substance_tags":"psilocybin","source_name":"Europe PMC","date_added":"2026-07-01 13:00:05","last_checked":"2026-07-08 01:20:23","raw_json":"{\"europe_pmc_id\":\"42380668\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}","topic_tags":"Depression,Anxiety,PTSD,Emotional Processing,Clinical Trial,Review Article","study_type":"Clinical Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":null},{"id":3662,"title":"Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms","normalized_title":"efficacy in relapse prevention psilocybin in alcohol use disorder with depressive symptoms","authors":"Centre Hospitalier Universitaire de Nīmes","abstract":"Up to 40% of individuals with alcohol use disorder (AUD) experience depression, which increases the risk of early relapse. Depression can cause relapse to occur 3 times faster in individuals with AUD who experience depressive symptoms at discharge. No treatments have been approved for individuals with both AUD and depression. Psilocybin, a psychedelic, shows promising results in treating both depression and addiction. It may be particularly effective for preventing relapse in people with AUD who also have depressive symptoms after detoxification, offering quicker action than traditional antidepressants. The Psilocybin Alcohol Depression (PAD) pilot study, launched in February 2024, has provided critical insights for avoiding methodological flaws and demonstrated that psilocybin-assisted psychotherapy (PAP) is both feasible and acceptable. Preliminary efficacy analyses were conducted: at 12 weeks, the 25 mg group showed significantly greater reductions in drinking days (p = 0.038) and craving frequency (p = 0.045). Relapse rates were 35% in the 25 mg group and 50% in the control group (HR = 0.52 \\[0.16-1.65\\]). In the ERPPAD trial, the study authors will compare high-dose PAP with low-dose PAP in preventing relapse in individuals with AUD and depressive symptoms. The hypothesis is that high-dose PAP will be more effective than low-dose in preventing relapse over 6 months.","journal":"ClinicalTrials.gov","publication_date":"2026-06-30","publication_year":2026,"doi":null,"pubmed_id":null,"source_url":"https://clinicaltrials.gov/study/NCT07638553","keywords":"Alcohol Use Disorder, Depressive Sympotoms, Psilocybin, Psilocybin (high dose), Psilocybin (low dose), RECRUITING","substance_tags":"psilocybin","source_name":"ClinicalTrials.gov","date_added":"2026-07-01 11:04:28","last_checked":"2026-07-07 01:23:04","raw_json":"{\"nct_id\":\"NCT07638553\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE3\"]}","topic_tags":"Depression,Addiction,Safety","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"clinical trial","openalex_id":null},{"id":3002,"title":"Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits.","normalized_title":"modeled long term effects of psilocybin on dynamic activity and effective connectivity of fronto striatal thalamic circuits","authors":"Pasquini L, Vohryzek J, Escrichs A, Perl YS, Ponce-Alvarez A, Idesis S, Girn M, Roseman L, Mitchell JM, Gazzaley A, Kringelbach M, Nutt DJ, Lyons T, Carhart-Harris RL, Deco G.","abstract":"Psilocybin has been shown to induce fast and sustained symptoms improvements across various psychiatric conditions, yet its long-term mechanisms of action are not fully understood. Initial evidence suggests that longitudinal functional and structural brain changes implicate fronto-striatal-thalamic (FST) circuitry, a broad system involved in goal-directed behavior and motivational states. Here, we performed secondary analyses and applied computational modeling to resting-state fMRI data from a within-subject longitudinal psilocybin trial in psychedelic-naïve healthy volunteers. We first showed that dynamic FST activity increased 4 weeks after a full dose of psilocybin. We then proceeded to mechanistically account for these changes by providing tentative model-based support that reductions in the structure-function coupling contribute to increased dynamic FST activity postpsilocybin. Finally, we used computational approaches to show that psilocybin induces longitudinal increases in bottom-up and reduced top-down modulation of FST circuits. We then used publicly available receptor maps to show that cortical reductions in top-down modulation are linked to regional 5-HT2A receptor availability, while increased information outflow via subcortical and limbic regions relates to local D2 receptor availability. Together, these findings suggest that increased FST flexibility weeks after a high dose of psilocybin is linked to serotonergic-mediated decreases in top-down information flow and dopaminergic-mediated increases in bottom-up information flow. This long-term functional re-organization of FST circuits may represent a common mechanism contributing to the potential clinical efficacy of psilocybin across various neuropsychiatric disorders including substance abuse, major depression, and anorexia nervosa.","journal":null,"publication_date":"2026-06-30","publication_year":2026,"doi":"10.1002/hbm.70596","pubmed_id":"42381187","source_url":"https://doi.org/10.1002/hbm.70596","keywords":"Thalamus, Corpus Striatum, Frontal Lobe, Nerve Net, Neural Pathways, Humans, Hallucinogens, Magnetic Resonance Imaging, Longitudinal Studies, Models, Neurological, Adult, Female, Male, Young Adult, Connectome, Psilocybin","substance_tags":"psilocybin","source_name":"Europe PMC","date_added":"2026-07-01 11:03:06","last_checked":"2026-07-08 01:20:22","raw_json":"{\"europe_pmc_id\":\"42381187\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}","topic_tags":"Depression,Eating Disorders,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Aging,Healthy Volunteers","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":null},{"id":58,"title":"MFCC-DFT mapping of ligand recognition at the 5-HT2A receptor: energetic analysis of the interactions between serotonin, psychedelics, and antipsychotics.","normalized_title":"mfcc dft mapping of ligand recognition at the 5 ht2a receptor energetic analysis of the interactions between serotonin psychedelics and antipsychotics","authors":"Junior WSC, Bezerra KS, Matias EGC, Oliveira JIN, Fulco UL.","abstract":"Mental disorders represent a major global health problem, with depression being one of the most prevalent and disabling conditions worldwide. Growing evidence suggests that the serotonergic system, particularly the 5-HT2A receptor, plays an important role in modulating mood and cognitive processes, constituting a key pharmacological target for several psychoactive compounds. In this study, we investigated the molecular interaction profile between the 5-HT2A receptor and four pharmacologically relevant ligands, serotonin (5-HT), psilocybin/psilocin (PSILO), lysergic acid diethylamide (LSD), and lumateperone (LMTP). Interaction energies were evaluated using the molecular fragmentation with conjugated caps (MFCC) method combined with density functional theory (DFT) calculations. Crystallographic structures were used as initial models, and residue-level interaction energies were calculated to identify the amino acids that contribute most to ligand stabilization at the receptor binding site. The results reveal that the complexes exhibit total interaction energies ranging from -35.38 to -71.98 kcal mol-1 under dielectric conditions representative of the protein environment. Key residues such as Asp155, Phe339, Leu229, and Val366 were identified as the main contributors to ligand stabilization in the studied systems, highlighting their role as structural anchors within the orthosteric binding pocket. Energy decomposition further revealed distinct interaction patterns associated with different regions of the ligand. Therefore, this study provides a detailed energetic characterization of ligand recognition in the 5-HT2A receptor and offers details that may contribute to the rational design of new serotonergic agents with potential for therapeutic applications.","journal":null,"publication_date":"2026-06-30","publication_year":2026,"doi":"10.1039/d6cp00943c","pubmed_id":"42300394","source_url":"https://doi.org/10.1039/d6cp00943c","keywords":"Humans, Serotonin, Lysergic Acid Diethylamide, Receptor, Serotonin, 5-HT2A, Antipsychotic Agents, Hallucinogens, Ligands, Binding Sites, Thermodynamics, Psilocybin, Heterocyclic Compounds, 4 or More Rings, Density Functional Theory","substance_tags":"psilocybin,psilocin","source_name":"Europe PMC","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-08 01:20:23","raw_json":"{\"europe_pmc_id\":\"42300394\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}","topic_tags":"Depression,Receptor Pharmacology,Drug Interactions","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":null},{"id":20,"title":"Psilocybin as a novel treatment for chronic pain.","normalized_title":"psilocybin as a novel treatment for chronic pain","authors":"Askey T, Lasrado R, Maiarú M, Stephens GJ","abstract":"Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti-nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co-morbid with pain. This review primarily explores the utility of preclinical animal models in investigating the potential of psilocybin as an anti-nociceptive agent. Initial studies involving psilocybin in animal models of neuropathic and inflammatory pain are summarised, alongside areas where further research is needed. The potential mechanisms of action, including targeting serotonergic pathways through the activation of 5-HT receptors at both spinal and central levels, as well as neuroplastic actions that improve functional connectivity in brain regions involved in chronic pain, are considered. Current clinical aspects and the translational potential of psilocybin from animal models to chronic pain patients are reviewed. Also discussed is psilocybin's profile as an ideal anti-nociceptive agent, with a wide range of effects against chronic pain and its associated inflammatory or emotional components. LINKED ARTICLES: This article is part of a themed issue Emerging Therapeutic Opportunities for Psychedelic and Related Drugs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.14/issuetoc.","journal":"British journal of pharmacology","publication_date":"2026-06-30","publication_year":2026,"doi":"10.1111/bph.17420","pubmed_id":"39614355","source_url":"https://pubmed.ncbi.nlm.nih.gov/39614355/","keywords":"neuropathic pain, neuroplasticity, nociplastic pain, psilocybin, psychedelic drugs, serotonergic signalling","substance_tags":"psilocybin","source_name":"PubMed","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-08 01:20:06","raw_json":"{\"pubmed_id\":\"39614355\"}","topic_tags":"Depression,Chronic Pain,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Emotional Processing,Review Article,Animal Study,Inflammation","study_type":"Review Article","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":null},{"id":19,"title":"The Australia story: Current status and future challenges for the clinical applications of psychedelics.","normalized_title":"the australia story current status and future challenges for the clinical applications of psychedelics","authors":"Nutt DJ, Hunt P, Schlag AK, Fitzgerald P","abstract":"The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4-methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic Goods Administration (TGA) approved the use of psilocybin for treatment-resistant depression and MDMA for PTSD to take effect from 1 July 2023. The campaign for TGA approval was led by a coalition comprising the Australian charity Mind Medicine Australia with support from Professor David Nutt, Drug Science, Professor Arthur Christopolous, Professor Chris Langmead (both from Monash University) and from large numbers of clinical, academic and patient groups. Under the rescheduling, current prescribing rights are limited to psychiatrists who have become authorised prescribers under the TGA's Authorised Prescriber Scheme, and psilocybin can only be used for treatment resistant depression and MDMA can only be used for PTSD. This paper reviews the background for this decision, its implications for approvals in other jurisdictions, as well as for the development pathways for other psychedelic drugs. LINKED ARTICLES: This article is part of a themed issue Emerging Therapeutic Opportunities for Psychedelic and Related Drugs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.14/issuetoc.","journal":"British journal of pharmacology","publication_date":"2026-06-30","publication_year":2026,"doi":"10.1111/bph.17398","pubmed_id":"39701143","source_url":"https://pubmed.ncbi.nlm.nih.gov/39701143/","keywords":"3,4-methylenedioxymethamphetamine (MDMA), Australia, psilocybin, psychedelics, therapeutic goods administration (TGA)","substance_tags":"psilocybin","source_name":"PubMed","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-08 01:20:06","raw_json":"{\"pubmed_id\":\"39701143\"}","topic_tags":"Depression,PTSD,Mechanism of Action,Review Article,Treatment-Resistant Depression","study_type":"Review Article","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":null},{"id":18,"title":"Neuropsychopharmacology of hallucinogenic and non-hallucinogenic 5-HT receptor agonists.","normalized_title":"neuropsychopharmacology of hallucinogenic and non hallucinogenic 5 ht receptor agonists","authors":"Sharp T, Ippolito A","abstract":"Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s. However, these drugs are now experiencing a renaissance in the field of psychiatry based on increasing evidence that they can produce long-lasting improvements in health across a wide variety of mental illnesses, including major depression, addictions and anxiety disorders. These drugs interact with many different 5-HT receptor subtypes but the powerful psychedelic experience, which (depending on set and setting) includes profound alterations in perception, mood and cognition, accompanied by vivid hallucinations, is now widely considered mediated by an agonist action at 5-HT receptors. However, the link between the psychedelic experience, 5-HT receptor agonism and therapeutic effects is currently uncertain. Indeed, recent research has revealed a new class of 5-HT receptor agonists which appear to retain the therapeutic potential of psychedelics drugs without inducing disorienting hallucinatory experiences. Biased signalling, partial agonism and non-selectivity at the 5-HT receptor are amongst the possible explanations for the differential properties of these drugs, whereas increased neuroplasticity offers a likely account of their common therapeutic effects. This article explores the neuropsychopharmacological properties of hallucinogenic and non-hallucinogenic 5-HT receptor agonists in the context of their promise as novel drug treatments in psychiatry. LINKED ARTICLES: This article is part of a themed issue Emerging Therapeutic Opportunities for Psychedelic and Related Drugs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.14/issuetoc.","journal":"British journal of pharmacology","publication_date":"2026-06-30","publication_year":2026,"doi":"10.1111/bph.70050","pubmed_id":"40405723","source_url":"https://pubmed.ncbi.nlm.nih.gov/40405723/","keywords":"5-HT, 5-HT2A receptor, antidepressant, hallucinogens, psychedelics, serotonin","substance_tags":"psilocin","source_name":"PubMed","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-08 01:20:06","raw_json":"{\"pubmed_id\":\"40405723\"}","topic_tags":"Depression,Anxiety,Addiction,Neuroplasticity,Pharmacology,Receptor Pharmacology","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":null},{"id":17,"title":"Psychedelics, entactogens and psychoplastogens for depression and related disorders.","normalized_title":"psychedelics entactogens and psychoplastogens for depression and related disorders","authors":"Hoyer D","abstract":"Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N-dimethyltryptamine, ayahuasca; non-hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g. ibogaine, ketamine and esketamine; and other atypicals e.g. dextromorphan/bupropion, esmethadone. Late-stage clinical trials support psychedelics and/or MDMA-assisted psychotherapy as rapidly acting treatments for major depressive disorder (MDD), treatment-resistant depression (TRD), PTSD or generalised anxiety disorders (GAD). Psilocybin, MDMA and LSD were granted FDA breakthrough status for TRD/MDD, PTSD and GAD, respectively, although FDA recently rejected the new drug application of MDMA in PTSD. Most of these drugs target the 5-HT and monoamine systems. Classical psychedelics act as 5-HT receptor agonists, although LSD, DMT and psilocybin target other 5-HT and/or dopamine receptors. Psychedelic-dependent 5-HT receptor agonism also has profound anti-(neuro)inflammatory effects. Advanced imaging studies suggest that brain 5-HT levels are reduced in depression. Functional magnetic resonance studies show that neural networks (cortico thalamic, salience, default mode) are profoundly impaired in depression. Such network defects are corrected upon psychedelic/entactogen treatment, offering a unique opportunity to serve as biomarkers for depression, anxiety and PTSD precision medicine trials. Psychedelics and entactogens target common end pathways, namely neuroplasticity/synaptogenesis, either directly via monoamine or glutamate receptors and/or indirectly, via BDNF and mTORC1 pathways. Together, these findings strongly support a biological basis for MDD, GAD, PTSD and related conditions, which can be considered as mixed biochemical, neurological and neuroimmune disorders, and are profoundly modified by psychedelics, entactogens and the newly developed psychoplastogens. LINKED ARTICLES: This article is part of a themed issue Emerging Therapeutic Opportunities for Psychedelic and Related Drugs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.14/issuetoc.","journal":"British journal of pharmacology","publication_date":"2026-06-30","publication_year":2026,"doi":"10.1111/bph.70088","pubmed_id":"40518133","source_url":"https://pubmed.ncbi.nlm.nih.gov/40518133/","keywords":"5-HT (serotonin), Brain-derived neurotrophic factor (BDNF), Empathogens, Entactogens, LSD (lysergic acid diethylamide), MDMA (3,4-methylenedioxy methamphetamine), Post-traumatic stress disorders (PTSD), Psychedelics, Psychoplastogens, Treatment resistant depression (TRD)","substance_tags":"psilocybin","source_name":"PubMed","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-08 01:20:06","raw_json":"{\"pubmed_id\":\"40518133\"}","topic_tags":"Depression,Anxiety,PTSD,Neuroplasticity,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Biomarkers,Aging,Clinical Trial,Treatment-Resistant Depression,Inflammation,Immune Function","study_type":"Clinical Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":null},{"id":14,"title":"Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology.","normalized_title":"psychedelics as pharmacotherapeutics for substance use disorders a scoping review on clinical trials and perspectives on underlying neurobiology","authors":"Wittenkeller L, Gudelsky G, Winhusen TJ, Amato D","abstract":"Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment-resistant depression because of their ability to alter consciousness and afflicted cognitive processes with lasting effects. We aimed to characterise how psychedelics are currently being investigated to treat substance use disorders (SUDs). Additionally, we aimed to summarise the available literature on the dopaminergic consequences of classic psychedelics in the nucleus accumbens (NAc), a foundational component of SUDs, to understand how psychedelics may be therapeutically relevant for SUDs from a neurobiological perspective. Two scoping review approaches adhering to PRISMA-SCR guidelines were conducted. The first screened for ongoing clinical trials utilising psychedelics for SUD treatment registered at ClinicalTrials.gov. The second screened for in vivo microdialysis studies measuring psychedelic-induced changes in extracellular NAc dopamine in rats, found using PubMed, SCOPUS or Google Scholar. Thirty-four unique clinical trials were identified targeting alcohol, cannabis, cocaine, methamphetamine, nicotine, and opioid use disorders and mostly consisting of open-label trials lacking placebo-treated controls. The most common SUD investigated was alcohol use disorder (AUD). Following stringent exclusion criteria, four publications were identified that measured extracellular dopamine in the NAc following systemic administration of psilocybin or 3,4-methylenedioxymethamphetamine (MDMA). A sustained mild increase of dopamine was observed that was unique to high-dose psilocybin. In addition to known therapeutic mechanisms of psychedelics, findings herein suggest that psilocybin may support dopamine homeostasis through restoration of tonic dopamine levels. LINKED ARTICLES: This article is part of a themed issue Emerging Therapeutic Opportunities for Psychedelic and Related Drugs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.14/issuetoc.","journal":"British journal of pharmacology","publication_date":"2026-06-30","publication_year":2026,"doi":"10.1111/bph.70181","pubmed_id":"40891276","source_url":"https://pubmed.ncbi.nlm.nih.gov/40891276/","keywords":"MDMA, addiction, psilocybin, psychedelics, psychedelic-assisted therapy, substance use disorders","substance_tags":"psilocybin","source_name":"PubMed","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-08 01:20:06","raw_json":"{\"pubmed_id\":\"40891276\"}","topic_tags":"Depression,Addiction,Mechanism of Action,Consciousness,Clinical Trial,Review Article,Treatment-Resistant Depression","study_type":"Clinical Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":null},{"id":8,"title":"Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants.","normalized_title":"acute dose dependent effects of 4 bromo 2 5 dimethoxyphenethylamine 2c b compared with 3 4 methylenedioxymethamphetamine mdma and psilocybin in a double blind placebo controlled study in healthy participants","authors":"Arikci D, Borgulya J, Straumann I, Vizeli P, Luethi D, Thomann J, Rudin D, Vukalovic I, Eckert A, Liechti ME, Holze F","abstract":"Based on its in vitro profile and preliminary evidence, 4-bromo-2,5-dimethoxyphenethylamine (2C-B) may have psychoactive properties that are similar to 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin, which are investigated for the treatment of posttraumatic stress disorder and depressive disorders. We compared acute effects of 2C-B (10, 20, and 30 mg), 125 mg MDMA, and 25 mg psilocybin in 24 healthy participants (12 women, 12 men) using a double-blind, randomized, placebo-controlled, crossover design. Outcome measures included acute subjective effects, autonomic effects, adverse effects, effects on emotional and cognitive empathy, plasma oxytocin and neurophysin I concentrations, and pharmacokinetics up to 9 h. 2C-B produced dose-dependent subjective effects, with the 30 mg dose exerting comparable \"any drug effects\" to MDMA but lower \"any drug effects\" than psilocybin. Only psilocybin induced \"bad drug effects\" and \"anxiety\" compared with placebo. The 30 mg dose of 2C-B induced psychedelic-type alterations of state of consciousness and increased emotional empathy similarly to MDMA. The average subjective effect duration of 30 mg 2C-B was 4.9 h and similar to MDMA (4.8 h) and shorter than psilocybin (6.1 h). MDMA produced the highest cardiovascular stimulation, followed by psilocybin and 2C-B. Only MDMA increased plasma oxytocin and neurophysin I concentrations. 2C-B exhibited dose-proportional pharmacokinetics, with a plasma elimination half-life of ~1.3 h. The 30 mg dose of 2C-B induced entactogenic and psychedelic effects similarly to MDMA and psilocybin, respectively. MDMA is more cardiostimulant than psilocybin and 2C-B. At the tested dose-level, psilocybin is more distressing than MDMA and 2C-B. These results may assist with dose-finding for future 2C-B research and provide a direct comparison with standard doses of the prototypical compounds MDMA and psilocybin. Trial registration: ClinicalTrials.gov identifier: NCT05523401.","journal":"Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology","publication_date":"2026-06-30","publication_year":2026,"doi":"10.1038/s41386-026-02428-9","pubmed_id":"42049943","source_url":"https://pubmed.ncbi.nlm.nih.gov/42049943/","keywords":"","substance_tags":"psilocybin","source_name":"PubMed","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-08 01:20:05","raw_json":"{\"pubmed_id\":\"42049943\"}","topic_tags":"Depression,Anxiety,PTSD,Pharmacology,Consciousness,Emotional Processing,In Vitro Study,Healthy Volunteers","study_type":"Clinical Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":null},{"id":302,"title":"Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats.","normalized_title":"chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats","authors":"Ladislavová L, Kútná V, Mazochová K, Šíchová K, Danda H, Lhotková E, Uttl L, Brejtr V, Syrová K, Mazoch V, Horsley R, Páleníček T.","abstract":"Psilocin (4-hydroxy-N, N-dimethyltryptamine) is a substituted tryptamine alkaloid and a nonselective serotonergic agonist acting predominantly at 5-HT2A/C receptors, with substantial binding to 5-HT1A and 5-HT2B receptors. Microdosing is the practice of taking a very small, sub-perceptual dose, typically 5% to 10% of a full recreational dose, to improve mood, creativity, and focus without hallucinogenic effects. However, rigorous preclinical evidence for its behavioral and neurobiological effects remains limited. We therefore examined whether chronic psilocin microdosing alters behavior and dentate gyrus (DG) cell proliferation in adult male Wistar rats. Psilocin was administered subcutaneously at 0.05 or 0.075 mg/kg. Animals received six doses of psilocin or saline on alternate days over 18 days prior to the first behavioral assessment, and microdosing on alternate days continued between behavioral tasks for five weeks. To minimize acute drug effects, all behavioral assessments were performed 48 h after the preceding dose. Animals were tested sequentially in the Elevated Plus Maze, Hole-Board, Open Field, Social Interaction, and modified Forced Swim Test, with six-day intervals between tests. DG cell proliferation was quantified by BrdU and Ki-67 immunohistochemistry. Across this regimen, psilocin microdosing did not measurably affect locomotor activity, depressive-like behavior, sociability, or novelty seeking, and it did not increase DG proliferation by either marker. A small anxiogenic effect was detected in the Elevated Plus Maze. These data indicate that, under the present dosing schedule and endpoints, chronic psilocin microdosing produces limited behavioral effects and does not enhance hippocampal progenitor proliferation in rats.","journal":null,"publication_date":"2026-06-29","publication_year":2026,"doi":"10.1016/j.pbb.2026.174231","pubmed_id":"42379524","source_url":"https://doi.org/10.1016/j.pbb.2026.174231","keywords":"","substance_tags":"psilocin","source_name":"Europe PMC","date_added":"2026-07-01 06:48:03","last_checked":"2026-07-07 01:20:35","raw_json":"{\"europe_pmc_id\":\"42379524\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}","topic_tags":"Depression,Neurogenesis,Receptor Pharmacology,Biomarkers,Microdosing,Creativity,Animal Study,Drug Interactions","study_type":"Animal Study","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":null},{"id":3561,"title":"The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease","normalized_title":"the efficacy of psilocybin therapy for depression in parkinson s disease","authors":"Yale University","abstract":"The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy. This is a randomized controlled trial of oral psilocybin therapy for depression in people with Parkinson's disease (PD). The primary goal is to examine efficacy of psilocybin therapy in this patient population. Investigators will enroll participants with clinically diagnosed early to moderate stage Parkinson's disease (Hoehn and Yahr Stage 1-3 during an \"on\" period), who meet criteria for moderate or greater depression severity and meet all other inclusion and exclusion criteria at screening. Participants will complete two drug administration sessions where they will each receive a dose of oral psilocybin ranging from low (\"microdose\") to high in a medically monitored setting with psychotherapeutic support. Participants will also complete a series of psychotherapy sessions before and after each drug administration session. Clinical assessments will be used to quantify changes in depression as well as other relevant outcomes (non-motor and motor symptoms of PD, cognitive performance, quality of life). Follow-up will continue to 3 months after the second session. Endpoints will evaluate efficacy, safety, and tolerability of study procedures. After posting of these trial results, this data will be combined with the data from the trial at UCSF (NCT06455293) for publication purposes.","journal":"ClinicalTrials.gov","publication_date":"2026-06-28","publication_year":2026,"doi":null,"pubmed_id":null,"source_url":"https://clinicaltrials.gov/study/NCT07610369","keywords":"Depression, Parkinson's Disease (PD), Psilocybin (drug), 4-phosphoryloxy- N, N-dimethyltryptamine, NOT_YET_RECRUITING","substance_tags":"psilocybin","source_name":"ClinicalTrials.gov","date_added":"2026-07-01 11:04:28","last_checked":"2026-07-05 01:22:40","raw_json":"{\"nct_id\":\"NCT07610369\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"PHASE2\"]}","topic_tags":"Depression,Microdosing,Randomized Controlled Trial,Safety","study_type":"Randomized Controlled Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"clinical trial","openalex_id":null},{"id":24,"title":"Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex.","normalized_title":"psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex","authors":"Du Y, Zhao X, Yao Y, Li Y, Wang G, Zhang L.","abstract":"BackgroundPosttraumatic stress disorder (PTSD) and major depressive disorder are often comorbid in humans. Psilocybin reportedly has beneficial therapeutic effects on depression, possibly by promoting neuroplasticity. PTSD is associated with the dysregulation of neuroplasticity in the hippocampus and medial prefrontal cortex (mPFC). We hypothesized that psilocybin might reduce fear memory by promoting neuroplasticity in the hippocampus and mPFC.AimsWe investigated the effects of psilocybin on fear memory and explored its underlying mechanisms. We generated a mouse model of PTSD via auditory-cued fear conditioning and treated the mice with either vehicle or psilocybin (2.5 mg/kg, intraperitoneal) on day 0. Fear memory was assessed by the percentage of freezing time in response to conditioned stimuli. Fear memory tests were conducted on days 1, 6, and 7, after which the mice were sacrificed. To investigate the role of neuroplasticity in mediating the effects of psilocybin on fear memory, we assessed structural neuroplasticity and neuroplasticity-associated marker protein levels in the hippocampus and mPFC 7 days after a single dose of psilocybin.ResultsPsilocybin reduced the cue-induced fear response on days 1, 6, and 7. Psilocybin ameliorated the fear conditioning-induced decreases in neuroplasticity in the hippocampus and mPFC. Through Golgi-Cox staining, Western blotting, and immunofluorescence staining, we found that psilocybin increased dendritic branches and spine density, upregulated GluR1 and synapsin-1, enhanced brain-derived neurotrophic factor and mammalian target of rapamycin signaling, and promoted neurogenesis.ConclusionsA single dose of psilocybin reduces both the rapid and sustained fear memory in mice, at least in part by restoring neuroplasticity in the hippocampus and mPFC. These findings indicate that psilocybin has significant potential for use in the treatment of PTSD and other mental disorders characterized by fear memory.","journal":"Journal of Psychopharmacology","publication_date":"2026-06-27","publication_year":2026,"doi":"10.1177/02698811261453819","pubmed_id":"42365496","source_url":"https://doi.org/10.1177/02698811261453819","keywords":"","substance_tags":"psilocybin","source_name":"Europe PMC","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-05 01:20:22","raw_json":"{\"europe_pmc_id\":\"42365496\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W7166436963\",\"openalex_url\":\"https://openalex.org/W7166436963\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W170792860\",\"https://openalex.org/W1980452424\",\"https://openalex.org/W1994547251\",\"https://openalex.org/W2036499082\",\"https://openalex.org/W2051271111\",\"https://openalex.org/W2084108505\",\"https://openalex.org/W2112188963\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2592144218\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2901904956\",\"https://openalex.org/W2927237494\",\"https://openalex.org/W2936046802\",\"https://openalex.org/W2963792090\",\"https://openalex.org/W2992679405\",\"https://openalex.org/W2997242667\",\"https://openalex.org/W3003581149\",\"https://openalex.org/W3011668650\",\"https://openalex.org/W3094714065\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3100215548\",\"https://openalex.org/W3108222140\",\"https://openalex.org/W3112503127\",\"https://openalex.org/W3112535936\",\"https://openalex.org/W3126370177\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3157927787\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3165027302\",\"https://openalex.org/W3169261903\",\"https://openalex.org/W3178121559\",\"https://openalex.org/W3179469168\",\"https://openalex.org/W3210509042\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4214649547\",\"https://openalex.org/W4231265947\",\"https://openalex.org/W4283070601\",\"https://openalex.org/W4308146113\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4318755662\",\"https://openalex.org/W4362457938\",\"https://openalex.org/W4394693583\",\"https://openalex.org/W4396588878\",\"https://openalex.org/W4400729513\",\"https://openalex.org/W4401212791\"],\"authorships\":[{\"id\":\"https://openalex.org/A5134867509\",\"display_name\":\"Y J Du\",\"orcid\":null},{\"id\":\"https://openalex.org/A5103220890\",\"display_name\":\"Xinyi Zhao\",\"orcid\":\"https://orcid.org/0009-0007-6483-6148\"},{\"id\":\"https://openalex.org/A5127702000\",\"display_name\":\"Yishan Yao\",\"orcid\":null},{\"id\":\"https://openalex.org/A5139523749\",\"display_name\":\"Yunfeng Li\",\"orcid\":null},{\"id\":\"https://openalex.org/A5088725738\",\"display_name\":\"Guyan Wang\",\"orcid\":\"https://orcid.org/0000-0003-3098-5472\"},{\"id\":\"https://openalex.org/A5101545617\",\"display_name\":\"Liming Zhang\",\"orcid\":\"https://orcid.org/0000-0002-9071-8985\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811261453819\",\"is_oa\":false}}}","topic_tags":"Depression,PTSD,Neuroplasticity,Neurogenesis,Mechanism of Action,Biomarkers,Animal Study","study_type":"Animal Study","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7166436963"},{"id":3522,"title":"Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]","normalized_title":"psilocybin assisted therapy for physician well being and burnout feasibility safety clinical effectiveness and biomarkers of response pat b psilocybin assisted therapy for physician well being and burnout","authors":"University of California, San Diego","abstract":"Through an open-label study involving a small group of UCSD physicians experiencing burnout, the investigators will evaluate the feasibility, safety, and preliminary effectiveness of PAT to reduce burnout symptoms. Physician burnout is a critical issue. Research shows that physician burnout is increasing, that physicians suffer higher rates of burnout than the general population, and that physician burnout is associated with poor mental health outcomes. Psilocybin is a naturally occurring alkaloid within certain fungi that elicits acute perceptual, cognitive, and emotional changes when ingested, due to action on neurotransmitter and neurocirculatory systems. The combination of psilocybin with psychological support, termed Psilocybin-Assisted Therapy (PAT), is a promising new mental health intervention shown to produce rapid and sustained improvements in psychological domains affected in burnout. PAT demonstrates preliminary efficacy as a treatment for depression and substance use disorders, is associated with brain changes measured with electroencephalography (EEG) and is a strong candidate treatment for physician burnout. The primary aim of this study is to investigate the safety, feasibility, and preliminary efficacy of PAT to enhance well-being in University of California, San Diego (UCSD) physicians experiencing burnout. A secondary aim is to identify neurophysiological changes associated with response to PAT. Physicians experiencing burnout will be recruited in an open-label trial involving preparatory therapy sessions, psilocybin treatment, and post-treatment integration. Burnout will be measured with the Stanford Professional Fulfillment Index (PFI).","journal":"ClinicalTrials.gov","publication_date":"2026-06-25","publication_year":2026,"doi":null,"pubmed_id":null,"source_url":"https://clinicaltrials.gov/study/NCT06814522","keywords":"Burnout, Burnout, Healthcare Workers, Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate, Psilocybin, RECRUITING","substance_tags":"psilocybin","source_name":"ClinicalTrials.gov","date_added":"2026-07-01 11:04:27","last_checked":"2026-07-02 23:06:03","raw_json":"{\"nct_id\":\"NCT06814522\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE1\",\"PHASE2\"]}","topic_tags":"Depression,Addiction,Brain Imaging,Biomarkers,Wellbeing,Emotional Processing,Healthcare Workers,Safety","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"clinical trial","openalex_id":null}],"total":1425,"page":1,"per_page":20,"pages":72,"resource":"papers","filters":{"q":null,"author":null,"substances":["psilocybin","psilocin"],"topic":"Depression","study_type":null,"cited_doi":null,"sources":[],"publication_statuses":[],"year":null,"journal":null,"from":null,"to":null,"added_from":null,"added_to":null,"sort":"newest","page":1,"per_page":"20"}}